James Januzzi, MD
Enriched profileHutter Family Professor of Medicine, Harvard Medical School; Cardiologist, Massachusetts General Hospital Heart Center (member of the Cardiology Division since 2000) · Massachusetts General Hospital
James Januzzi is Hutter Family Professor of Medicine, Harvard Medical School; Cardiologist, Massachusetts General Hospital Heart Center (member of the Cardiology Division since 2000) at Massachusetts General Hospital. OpenAlex indexes 1,175 publications with 102,327 citations (h-index 136); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Cardiovascular Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
James L. Januzzi Jr., MD, is Hutter Family Professor of Medicine, Harvard Medical School at Massachusetts General Hospital (Heart Center / Cardiology Division), with a Harvard Medical School faculty appointment. The public record shows 1,175 publications with 102,327 citations (h-index 136), centered on Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Acute Myocardial Infarction Research. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 45 companies.
- Most recent indexed publication: 2026 · Circulation. Population health and outcomes
- Top research focus: Heart Failure Treatment and Management
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 45 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 57 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 673.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Transform: Teaching, Technology, and Teams
Sponsor: American College of Cardiology
- DEFINing the PrEvalence and Characteristics of Coronary Artery Disease Among Patients With TYPE 2 Myocardial Infarction Using CT-FFR
Sponsor: Massachusetts General Hospital
- Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
Sponsor: Applied Therapeutics, Inc.
Industry payments
Updated 27 Aug 2026
45 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20257 payments$49,600openpaymentsdata.cms.gov ↗
- ROCHE DIAGNOSTICS INTERNATIONAL LTDProgram year20253 payments$11,256openpaymentsdata.cms.gov ↗
- Abbott LaboratoriesProgram year20258 payments$10,809openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79.4%Statin19.3%Atorvastatin Calcium71%Rosuvastatin Calcium22%Simvastatin3%Pitavastatin Calcium2%Pravastatin Sodium2%Part D<11 patientsBeta blocker13.8%Metoprolol Succinate79%Carvedilol11%Atenolol10%Part D≥88 patientsBlood & clotting
11.2%Factor Xa inhibitor9.5%Eliquis69%Xarelto31%Part D≥52 patientsP2Y12 inhibitor1.1%Clopidogrel100%Part D≥11 patientsMetabolism & gastrointestinal
8.9%SGLT2 inhibitor6.6%Jardiance85%Farxiga15%Part D<11 patientsGLP-1 receptor agonist1.8%Ozempic66%Wegovy34%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
3 congress contributions (2020–2023) across ADA, ASCO per OpenAlex. The most recent:
- 1238-P: The Face of Diabetic Cardiomyopathy—Baseline Characteristics from the ARISE-HF Trial
ADA Scientific Sessions
ADA2023Co-authorPoster - 450-P: N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial
ADA Scientific Sessions
ADA2023Co-authorPoster - An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.
ASCO Annual Meeting
ASCO2020Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Cost-Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors by Ejection Fraction and Drug Pricing in the United States: A Systematic Review.
Circulation. Population health and outcomes
Review2026 - Evaluation of a New Antibody-Based NT-proBNP Assay for Acute Dyspnea in the Emergency Department.
Clinical chemistry
Article2026 - Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial.
Circulation
Clinical Trial2025 - Temporal Trends, Patient Characteristics, and Outcomes of Type 2 Versus Type 1 Myocardial Infarction Among Medicare Beneficiaries.
Circulation. Cardiovascular quality and outcomes
Article2025
Most-cited works
by citation count (OpenAlex)- 012013 ACCF/AHA Guideline for the Management of Heart FailureArticle12,637 citations2013
- 02Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureArticle5,104 citations2020
- 03Empagliflozin in Heart Failure with a Preserved Ejection FractionArticle4,695 citations2021
- 042013 ACCF/AHA Guideline for the Management of Heart Failure: Executive SummaryArticle3,304 citations2013
- 05Third universal definition of myocardial infarctionArticle3,076 citations2012
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/james-januzzi-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/James-Januzzi
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/james-januzzi-8485334
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
hfsa.org/james-l-januzzi-md-facc-fesc
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hfsa.org ↗ - Other
hcplive.com/view/moving-the-needle-in-medicine-mentorship-medicine-and-the-making-of-an-innovator-with-jim-januzzi-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →acc.org ↗
- Board Certified
Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneral.org ↗ - Fellow
American College of Cardiology (FACC) and Fellow, European Society of Cardiology (FESC)
Editorial & leadership roles
journal and society appointments- Associate Editor
Journal of the American College of Cardiology (JACC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →acc.org ↗ - Associate Editor
JACC: Heart Failure
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →acc.org ↗
Awards & honors
honors on the public record- 2025 Distinguished Clinical Scientist Award
American College of Cardiology (recognized for contributions to cardiac biomarker research)
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bioengineer.org ↗ - First incumbent
Hutter Family Professorship in Medicine in the Field of Cardiology, Harvard Medical School (invested Sept. 8)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hms.harvard.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
- Chief Scientific Officer and C. Michael Gibson Chair
Baim Institute for Clinical Research (matches ORCID-declared current employment)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →baiminstitute.org ↗ - Faculty
Harvard Clinical Research Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
Media & interviews
press, podcasts and appearances- Podcast guest
"Moving the Needle in Medicine: Mentorship, Medicine, and the Making of an Innovator, With Jim Januzzi, MD" (HCPLive)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗ - ACC ACCEL-Lite podcast interview with Drs. Januzzi and Stevenson
"Understanding the Optimal Evaluation and Management of Patients With HF"
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital
Keith Johnson, MD
Massachusetts General Hospital